PENZBERG, Germany--(BUSINESS WIRE)--The new xCELLigence System RTCA HT Instrument from Roche Diagnostics (SIX:RO)(SIX:ROG)(OTCQX:RHHBY) rounds out the company’s portfolio in real-time cell analysis with a high-throughput product. The new instrument merges the power and flexibility of xCELLigence System technology with high-throughput analyses and workflows for automated screening applications. The system allows researchers to run 1 to 4 plates independently on up to four RTCA HT stations, thus reading 4 x384 well plates in parallel. Integration with automated plate and liquid handling systems is also an option. The instrument was launched worldwide and will be available in all markets during the next months.

The cell-based xCELLigence System assays perfectly integrate micro electronics and cell biology, offering a number of advantages over conventional cell analysis systems. The system is suitable for uninterrupted monitoring of real-time kinetics and processes in living cells and supplies a densely concentrated stream of information. Sensitivity and reproducibility are excellent for monitoring the overall cell population of a cell culture.

“The new RTCA HT Instrument has the potential to become the benchmark system in real-time label-free, automated HTS and automated long-term cytotoxicity screening,” says Ruedi Stoffel, Life Cycle Leader for Cellular Analysis at Roche Diagnostics.

The heart of the system is a microelectronic biosensor built into each well of the E-Plate microtiter plates. A cell in contact with the sensor changes the electrical impedance between the microelectrodes. Each change in the cell’s status, e.g., changes in cell adhesion, cytotoxicity, cell proliferation, cell-to-cell interactions and morphological changes lead to changes in the impedance measurements and can therefore be easily and quickly detected in real-time. In combination with the RTCA DP Instrument and CIM-Plate 16, the xCELLigence System product line also allows cancer researchers to conduct direct studies of cell migration and invasion, eliminating the need for labeling cells, a process that can induce non-physiological changes in the cells.

For more information please go to www.xcelligence.roche.com

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80,000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

For life science research only. Not for use in diagnostic procedures.

XCELLIGENCE is a trademark of Roche.

E-PLATE and ACEA BIOSCIENCES are registered trademarks of ACEA Biosciences, Inc. in the US

Other brands or product names are trademarks of their respective holders.